Loading...

Everly, Matthew

Title(s)Associate Adjunct Professor, Medicine
SchoolNephrology
Phone310-267-1330
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Purnajo I, Beaumont JL, Polinsky M, Alemao E, Everly MJ. Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials. Am J Transplant. 2019 Dec 24. PMID: 31874117.
      View in: PubMed
    2. Raghu VK, Beaumont JL, Everly MJ, Venick RS, Lacaille F, Mazariegos GV. Pediatric intestinal transplantation: Analysis of the intestinal transplant registry. Pediatr Transplant. 2019 12; 23(8):e13580. PMID: 31531934.
      View in: PubMed
    3. Shin BH, Everly MJ, Zhang H, Choi J, Vo A, Zhang X, Huang E, Jordan SC, Toyoda M. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients with Chronic Antibody-Mediated Rejection. Transplantation. 2019 Aug 01. PMID: 31385933.
      View in: PubMed
    4. Nakamura K, Kageyama S, Ito T, Hirao H, Kadono K, Aziz A, Dery KJ, Everly MJ, Taura K, Uemoto S, Farmer DG, Kaldas FM, Busuttil RW, Kupiec-Weglinski JW. Antibiotic pretreatment alleviates liver transplant damage in mice and humans. J Clin Invest. 2019 07 22; 129(8):3420-3434. PMID: 31329160.
      View in: PubMed
    5. Schinstock CA, Dadhania DM, Everly MJ, Smith B, Gandhi M, Farkash E, Sharma VK, Samaniego-Picota M, Stegall MD. Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study. Transpl Int. 2019 May; 32(5):502-515. PMID: 30597643.
      View in: PubMed
    6. Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019 Mar; 69(3):1273-1286. PMID: 30229989.
      View in: PubMed
    7. Stegall MD, Troy Somerville K, Everly MJ, Mannon RB, Gaber AO, First MR, Agashivala N, Perez V, Newell KA, Morris RE, Sudan D, Romero K, Eremenco S, Mattera M, Spear N, Porter AC, O'Doherty I. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement. Am J Transplant. 2019 03; 19(3):625-632. PMID: 30549395.
      View in: PubMed
    8. Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, Stegall MD. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant. 2019 06; 19(6):1671-1683. PMID: 30412654.
      View in: PubMed
    9. Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts. Am J Transplant. 2018 09; 18(9):2305-2313. PMID: 29767445.
      View in: PubMed
    10. Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct. 2018 Jun; 4(6):e353. PMID: 30123826.
      View in: PubMed
    11. O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation. 2017 09; 101(9):2062-2070. PMID: 28452922.
      View in: PubMed
    12. Ravindranath MH, Jucaud V, Banuelos N, Everly MJ, Cai J, Nguyen A, Terasaki PI. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss. J Immunol. 2017 06 01; 198(11):4524-4538. PMID: 28476933.
      View in: PubMed
    13. Cheng EY, Everly MJ, Kaneku H, Banuelos N, Wozniak LJ, Venick RS, Marcus EA, McDiarmid SV, Busuttil RW, Terasaki PI, Farmer DG. Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients. Transplantation. 2017 04; 101(4):873-882. PMID: 27490417.
      View in: PubMed
    14. Everly MJ, Briley KP, Haisch CE, Dieplinger G, Bolin P, Kendrick SA, Morgan C, Maldonado AQ, Rebellato LM. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Transpl Int. 2017 Jun; 30(6):566-578. PMID: 28211192.
      View in: PubMed
    15. Schinstock CA, Cosio F, Cheungpasitporn W, Dadhania DM, Everly MJ, Samaniego-Picota MD, Cornell L, Stegall MD. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss. Am J Transplant. 2017 Jun; 17(6):1574-1584. PMID: 27977905.
      View in: PubMed
    16. Hamdorf M, Kawakita S, Everly M. The Potential of MicroRNAs as Novel Biomarkers for Transplant Rejection. J Immunol Res. 2017; 2017:4072364. PMID: 28191475.
      View in: PubMed
    17. Hussain SK, Makgoeng SB, Everly MJ, Goodman MT, Martínez-Maza O, Morton LM, Clarke CA, Lynch CF, Snyder J, Israni A, Kasiske BL, Engels EA. HLA and Risk of Diffuse Large B cell Lymphoma After Solid Organ Transplantation. Transplantation. 2016 Nov; 100(11):2453-2460. PMID: 26636741.
      View in: PubMed
    18. Hörmann M, Dieplinger G, Rebellato LM, Briley KP, Bolin P, Morgan C, Haisch CE, Everly MJ. Incidence and impact of anti-HLA-DP antibodies in renal transplantation. Clin Transplant. 2016 09; 30(9):1108-14. PMID: 27327607.
      View in: PubMed
    19. Lachmann N, Schönemann C, El-Awar N, Everly M, Budde K, Terasaki PI, Waiser J. Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. Nephrol Dial Transplant. 2016 08; 31(8):1351-9. PMID: 27190369.
      View in: PubMed
    20. Idica A, Everly MJ. Donor-Specific HLA Antibodies: A Review of Data Published in 2016. Clin Transpl. 2016; 32:13-22. PMID: 28564519.
      View in: PubMed
    21. Kawakita S, Everly MJ. Cytokines as Biomarkers for Renal Transplant Recipients: What is New? Clin Transpl. 2016; 32:23-30. PMID: 28564520.
      View in: PubMed
    22. Dieplinger G, Everly MJ, Briley KP, Haisch CE, Bolin P, Maldonado AQ, Kendrick WT, Kendrick SA, Morgan C, Terasaki PI, Rebellato LM. Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction. Transpl Infect Dis. 2015 Dec; 17(6):848-58. PMID: 26442607.
      View in: PubMed
    23. Cai J, Terasaki PI, Zhu D, Lachmann N, Schönemann C, Everly MJ, Qing X. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection. Exp Mol Pathol. 2016 Feb; 100(1):45-50. PMID: 26615783.
      View in: PubMed
    24. Pham PT, Everly M, Faravardeh A, Pham PC. Management of patients with a failed kidney transplant: Dialysis reinitiation, immunosuppression weaning, and transplantectomy. World J Nephrol. 2015 May 06; 4(2):148-59. PMID: 25949929.
      View in: PubMed
    25. Maehara C, Everly MJ. Alloantibodies in Organ Transplant: A Review of Data Published in 2015. Clin Transpl. 2015; 31:139-146. PMID: 28514575.
      View in: PubMed
    26. Khatiwala JR, Everly MJ. An Update on Cardiac Transplantation in the United States Based on an Analysis of the UNOS Registry. Clin Transpl. 2015; 31:27-34. PMID: 28514565.
      View in: PubMed
    27. Everly MJ. There is a Road, No Simple Highway: Envisioning a Path to Better Long-Term Organ Transplant Survival. Clin Transpl. 2015; 31:203-209. PMID: 28514582.
      View in: PubMed
    28. Taniguchi M, Rebellato LM, Briley KP, Haisch CE, Bolin P, Banuelos N, Hopfield J, Terasaki PI, Everly MJ. Risk Stratification of Human Leukocyte Antigen Class II Donor Specific Antibody Positive Patients by Immunoglobulin G Subclasses. Clin Transpl. 2015; 31:293-301. PMID: 28514591.
      View in: PubMed
    29. Dieplinger G, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI. Changes in successive measures of de novo donor-specific anti-human leukocyte antigen antibodies intensity and the development of allograft dysfunction. Transplantation. 2014 Nov 27; 98(10):1097-104. PMID: 24911039.
      View in: PubMed
    30. Bentall A, Tyan DB, Sequeira F, Everly MJ, Gandhi MJ, Cornell LD, Li H, Henderson NA, Raghavaiah S, Winters JL, Dean PG, Stegall MD. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int. 2014 Dec; 27(12):1235-43. PMID: 24990476.
      View in: PubMed
    31. Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Maldonado AQ, Harland RC, Terasaki PI. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients. Transplantation. 2014 Mar 15; 97(5):494-501. PMID: 24487396.
      View in: PubMed
    32. Andre M, Huang E, Everly M, Bunnapradist S. The UNOS Renal Transplant Registry: Review of the Last Decade. Clin Transpl. 2014; 1-12. PMID: 26281122.
      View in: PubMed
    33. Cheng EY, Everly MJ. Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry. Clin Transpl. 2014; 13-26. PMID: 26281123.
      View in: PubMed
    34. Cai J, Wu G, Qing A, Everly M, Cheng E, Terasaki P. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine. Clin Transpl. 2014; 33-47. PMID: 26281125.
      View in: PubMed
    35. Rebellato LM, Parker K, Everly MJ, Briley KP, Kendrick W, Kendrick S, Haisch CE, Terasaki PI, Bolin P. Improved Long-Term Survival in Kidney Transplant Recipients with Donor-Specific HLA Antibodies After Mycophenolic Acid Escalation. Clin Transpl. 2014; 137-42. PMID: 26281138.
      View in: PubMed
    36. Everly MJ. Update on Alloantibodies in Solid Organ Transplantation. Clin Transpl. 2014; 125-9. PMID: 26281136.
      View in: PubMed
    37. Hoshino J, Everly MJ, Kaneku H, Ubara Y, Takaichi K, Terasaki PI. Impact of the presence and duration of donor-specific antibodies on renal function. Transplant Proc. 2014 Jan-Feb; 46(1):75-80. PMID: 24507029.
      View in: PubMed
    38. Everly MJ. An Update on Cardiac Transplantation in the United States. Clin Transpl. 2014; 27-32. PMID: 26281124.
      View in: PubMed
    39. Wu P, Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Terasaki PI. Trends and characteristics in early glomerular filtration rate decline after posttransplantation alloantibody appearance. Transplantation. 2013 Nov 27; 96(10):919-25. PMID: 23912173.
      View in: PubMed
    40. Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clin Biochem. 2013 Oct; 46(15):1389-93. PMID: 23726814.
      View in: PubMed
    41. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, Briley KP, Haisch CE, Bolin P, Parker K, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013 May 15; 95(9):1113-9. PMID: 23514959.
      View in: PubMed
    42. Chaudhuri A, Ozawa M, Everly MJ, Ettenger R, Dharnidharka V, Benfield M, Mathias R, Portale A, McDonald R, Harmon W, Kershaw D, Vehaskari VM, Kamil E, Baluarte HJ, Warady B, Li L, Sigdel TK, Hsieh SC, Dai H, Naesens M, Waskerwitz J, Salvatierra O, Terasaki PI, Sarwal MM. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol. 2013 Mar; 24(4):655-64. PMID: 23449533.
      View in: PubMed
    43. Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013 Feb 15; 95(3):410-7. PMID: 23380861.
      View in: PubMed
    44. Cail J, Huang W, Terasaki PI, Everly MJ, Briley KP, Haisch CE, Bolin P, Kendrick WT, Kendrick SA, Morgan C, Harland RC, Rebellato LM. Novel biomarker combination predicts long-term allograft outcome. Clin Transpl. 2013; 319-24. PMID: 25095524.
      View in: PubMed
    45. Dieplinger G, Everly MJ. Understanding trends and predictors of outcome in elderly renal transplant recipients: an analysis of the UNOS registry. Clin Transpl. 2013; 1-11. PMID: 25095487.
      View in: PubMed
    46. Kawakita S, Everly MJ. Donor risk factors in orthotopic liver transplant: analysis of the OPTN/UNOS registry. Clin Transpl. 2013; 13-22. PMID: 25095488.
      View in: PubMed
    47. Hörmann M, Everly MJ. Heart transplantation in an aging society: an analysis of 25 years of the OPTN/UNOS registry. Clin Transpl. 2013; 31-44. PMID: 25095490.
      View in: PubMed
    48. Everly MJ. Incidence and hazards of alloantibodies in renal transplantation. Clin Transpl. 2013; 313-7. PMID: 25095523.
      View in: PubMed
    49. Piemonti L, Everly MJ, Maffi P, Scavini M, Poli F, Nano R, Cardillo M, Melzi R, Mercalli A, Sordi V, Lampasona V, Espadas de Arias A, Scalamogna M, Bosi E, Bonifacio E, Secchi A, Terasaki PI. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013 May; 62(5):1656-64. PMID: 23274902.
      View in: PubMed
    50. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation. 2012 Jun 15; 93(11):1173-8. PMID: 22592887.
      View in: PubMed
    51. Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation. 2012 Mar 27; 93(6):572-7. PMID: 22262128.
      View in: PubMed
    52. Everly MJ. Immunosuppression regimens to address alloantibodies in transplant recipients. Clin Transpl. 2012; 219-23. PMID: 23721025.
      View in: PubMed
    53. Everly MJ. Understanding and addressing the humoral immune response in transplant recipients. Clin Transpl. 2012; 225-7. PMID: 23721026.
      View in: PubMed
    54. Zhu D, Everly MJ. Deceased donor kidney transplantation in the United States from 1988 to 2011: an analysis of the OPTN/UNOS registry. Clin Transpl. 2012; 1-12. PMID: 23721006.
      View in: PubMed
    55. Kannabhiran D, Everly MJ, Walker-McDermott JK, Tiongko S, Friedlander R, Putheti P, Sharma V, Dadhania D. Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Clin Transpl. 2012; 229-35. PMID: 23721027.
      View in: PubMed
    56. Everly MJ, Terasaki PI. The state of therapy for removal of alloantibody producing plasma cells in transplantation. Semin Immunol. 2012 Apr; 24(2):143-7. PMID: 22153981.
      View in: PubMed
    57. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011 Dec; 30(12):1320-6. PMID: 21968130.
      View in: PubMed
    58. Everly MJ, Everly JJ, Terasaki PI. Role of proteasome inhibition in sensitized transplant candidates. Chin Med J (Engl). 2011 Mar; 124(5):771-4. PMID: 21518574.
      View in: PubMed
    59. Everly MJ. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients. Clin Transpl. 2011; 319-25. PMID: 22755425.
      View in: PubMed
    60. Everly MJ. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients. Clin Transpl. 2011; 333-6. PMID: 22755427.
      View in: PubMed
    61. Wu P, Everly MJ, Jin J, Mao Y, Chen J. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients. Clin Transpl. 2011; 365-8. PMID: 22755432.
      View in: PubMed
    62. Everly MJ, Terasaki PI, Hopfield J, Trivedi HL, Kaneku H. Protective immunity remains intact after antibody removal by means of proteasome inhibition. Transplantation. 2010 Dec 27; 90(12):1493-8. PMID: 21042236.
      View in: PubMed
    63. Trivedi HL, Terasaki PI, Feroz A, Vanikar AV, Trivedi VB, Khemchandani SI, Dave SD, Shankar V, Modi PR, Kaneku H, Idica A, Everly MJ. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients. Transplantation. 2010 Jul 27; 90(2):221-2. PMID: 20644455.
      View in: PubMed
    64. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation. 2010 Apr 27; 89(8):962-7. PMID: 20075791.
      View in: PubMed
    65. Everly MJ. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival. Clin Transpl. 2010; 317-22. PMID: 21696049.
      View in: PubMed
    66. Everly MJ. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers. Clin Transpl. 2010; 353-62. PMID: 21696053.
      View in: PubMed
    67. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009 Aug 27; 88(4):568-74. PMID: 19696641.
      View in: PubMed
    68. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009 May 27; 87(10):1555-61. PMID: 19461494.
      View in: PubMed
    69. Everly MJ, Terasaki PI. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol. 2009 Aug; 70(8):655-9. PMID: 19375466.
      View in: PubMed
    70. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant. 2009 May; 9(5):1063-71. PMID: 19344434.
      View in: PubMed
    71. Ravindranath MH, Everly MJ. Heart transplantation in the United States from 1998 to 2008. Clin Transpl. 2009; 65-74. PMID: 20524277.
      View in: PubMed
    72. Trivedi HL, Kaneku H, Terasaki PI, Feroz A, Vanikar AV, Trivedi VB, Khemchandani SI, Dave SD, Modi PR, Jahr F, Idica A, Everly MJ. Clonal deletion using total lymphoid irradiation with no maintenance immunosuppression in renal allograft recipients. Clin Transpl. 2009; 265-80. PMID: 20524291.
      View in: PubMed
    73. Everly MJ, Jahr F, Kaneku H, Trivedi HL, Terasaki PI. Removal of physiologic corticosteroid doses results in HLA antibody appearance and allograft dysfunction in patients transplanted under a clonal deletion protocol. Clin Transpl. 2009; 281-93. PMID: 20524292.
      View in: PubMed
    74. Everly MJ. A summary of bortezomib use in transplantation across 29 centers. Clin Transpl. 2009; 323-37. PMID: 20524294.
      View in: PubMed
    75. Patel JK, Everly MJ, Kittleson M, Kobashigawa JA. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report. Clin Transpl. 2009; 347-9. PMID: 20524297.
      View in: PubMed
    76. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc. 2009 Jan-Feb; 41(1):105-7. PMID: 19249489.
      View in: PubMed
    77. Everly MJ. Pancreas transplantation in the United States: an analysis of the UNOS registry. Clin Transpl. 2009; 75-81. PMID: 20527068.
      View in: PubMed
    78. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008 Dec 27; 86(12):1754-61. PMID: 19104417.
      View in: PubMed
    79. Kaneku H, Idica A, Everly MJ, Terasaki PI, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Trivedi HL. Donor-specific HLA antibody response in clonal deletion. Clin Transpl. 2008; 189-98. PMID: 19708456.
      View in: PubMed
    80. Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl. 2008; 229-39. PMID: 19708459.
      View in: PubMed
    81. Everly MJ. Cardiac transplantation in the United States: an analysis of the UNOS registry. Clin Transpl. 2008; 35-43. PMID: 19708444.
      View in: PubMed
    82. Zhu L, Lee PC, Everly MJ, Terasaki PI. Detailed examination of HLA antibody development on renal allograft failure and function. Clin Transpl. 2008; 171-87. PMID: 19711514.
      View in: PubMed
    83. Everly MJ, Bloom RD, Tsai DE, Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother. 2007 Nov; 41(11):1850-8. PMID: 17940127.
      View in: PubMed
    84. Everly MJ, Heaton PC, Cluxton RJ. Beta-blocker underuse in secondary prevention of myocardial infarction. Ann Pharmacother. 2004 Feb; 38(2):286-93. PMID: 14742768.
      View in: PubMed